 NEW HAVEN, Conn. , June 7, 2022 PRNewswire -- Trevi Therapeutics, Inc. Nasdaq: TRVI, a clinical-stage biopharmaceutical company developing an investigational therapy HaduvioTM nalbuphine ER for pruritus in prurigo nodularis PN and chronic cough in idiopathic pulmonary fibrosis IPF, today announced that Jennifer Good, President and CEO, will deliver a company presentation at 2022 BIO International Convention. 